» Articles » PMID: 35588797

Induction of Fibroblast Growth Factor Receptor 4 by Helicobacter Pylori Via Signal Transducer and Activator of Transcription 3 With a Feedforward Activation Loop Involving SRC Signaling in Gastric Cancer

Overview
Specialty Gastroenterology
Date 2022 May 19
PMID 35588797
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: Helicobacter pylori (H pylori) infection is the main risk factor for gastric cancer. The role of fibroblast growth factor receptors (FGRFs) in H pylori-mediated gastric tumorigenesis remains largely unknown. This study investigated the molecular and mechanistic links between H pylori, inflammation, and FGFR4 in gastric cancer.

Methods: Cell lines, human and mouse gastric tissue samples, and gastric organoids models were implemented. Infection with H pylori was performed using in vitro and in vivo models. Western blot, real-time quantitative reverse-transcription polymerase chain reaction, flow cytometry, immunofluorescence, immunohistochemistry, chromatin immunoprecipitation, and luciferase reporter assays were used for molecular, mechanistic, and functional studies.

Results: Analysis of FGFR family members using The Cancer Genome Atlas data, followed by validation, indicated that FGFR4 messenger (m)RNA was the most significantly overexpressed member in human gastric cancer tissue samples (P < .001). We also detected high levels of Fgfr4 mRNA and protein in gastric dysplasia and adenocarcinoma lesions in mouse models. Infection with J166, 7.13, and PMSS1 cytotoxin-associated gene A (CagA)+ H pylori strains induced FGFR4 mRNA and protein expression in in vitro and in vivo models. This was associated with a concordant activation of signal transducer and activator of transcription 3 (STAT3). Analysis of the FGFR4 promoter suggested several putative binding sites for STAT3. Using chromatin immunoprecipitation assay and an FGFR-promoter luciferase reporter containing putative STAT3 binding sites and their mutants, we confirmed a direct functional binding of STAT3 on the FGFR4 promoter. Mechanistically, we also discovered a feedforward activation loop between FGFR4 and STAT3 where the fibroblast growth factor 19–FGFR4 axis played an essential role in activating STAT3 in a SRC proto-oncogene non-receptor tyrosine kinase dependent manner. Functionally, we found that FGFR4 protected against H pylori-induced DNA damage and cell death.

Conclusions: Our findings demonstrated a link between infection, inflammation, and FGFR4 activation, where a feedforward activation loop between FGFR4 and STAT3 is established via SRC proto-oncogene non-receptor tyrosine kinase in response to H pylori infection. Given the relevance of FGFR4 to the etiology and biology of gastric cancer, we propose FGFR4 as a druggable molecular vulnerability that can be tested in patients with gastric cancer.

Citing Articles

FGF-based drug discovery: advances and challenges.

Chen G, Chen L, Li X, Mohammadi M Nat Rev Drug Discov. 2025; .

PMID: 39875570 DOI: 10.1038/s41573-024-01125-w.


infection as a contributing factor to metabolic dysfunction-associated steatohepatitis: A population-based insight.

Li C, Nan J, Xu B World J Hepatol. 2025; 17(1):103228.

PMID: 39871915 PMC: 11736478. DOI: 10.4254/wjh.v17.i1.103228.


Blockade of Src signaling prevented stemness gene expression and proliferation of patient-derived gastric cancer stem cells.

Hu C, Lin C, Shih H, You R, Wu W, Chen Y Tzu Chi Med J. 2025; 37(1):65-71.

PMID: 39850393 PMC: 11753518. DOI: 10.4103/tcmj.tcmj_133_24.


Helicobacter pylori and gastric cancer: mechanisms and new perspectives.

Duan Y, Xu Y, Dou Y, Xu D J Hematol Oncol. 2025; 18(1):10.

PMID: 39849657 PMC: 11756206. DOI: 10.1186/s13045-024-01654-2.


Molecular Mechanism for Malignant Progression of Gastric Cancer Within the Tumor Microenvironment.

Matsuoka T, Yashiro M Int J Mol Sci. 2024; 25(21).

PMID: 39519285 PMC: 11546171. DOI: 10.3390/ijms252111735.


References
1.
Polk D, Peek Jr R . Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer. 2010; 10(6):403-14. PMC: 2957472. DOI: 10.1038/nrc2857. View

2.
Babina I, Turner N . Advances and challenges in targeting FGFR signalling in cancer. Nat Rev Cancer. 2017; 17(5):318-332. DOI: 10.1038/nrc.2017.8. View

3.
Subbiah V, Pal S . Precision Oncology for Hepatocellular Cancer: Slivering the Liver by FGF19-FGF4-KLB Pathway Inhibition. Cancer Discov. 2019; 9(12):1646-1649. DOI: 10.1158/2159-8290.CD-19-1156. View

4.
Zaid T, Yeung T, Thompson M, Leung C, Harding T, Co N . Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer. Clin Cancer Res. 2013; 19(4):809-20. PMC: 3577959. DOI: 10.1158/1078-0432.CCR-12-2736. View

5.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View